Roivant Sciences Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 87S.F | 6IB.F | 9995.HK | 9969.HK | 0A3M.IL | ARGX | |
|---|---|---|---|---|---|---|
| Market cap | 24.37B | 17.27B | 40.23B | 21.56B | 25.17B | 58.57B |
| P/E (TTM) | — | 123.8 | 6.1 | 20.3 | 5.1 | 32.3 |
| Forward P/E | — | — | 46.7 | 53.2 | 5.1 | 28.0 |
| Price/book | 6.5 | 6.2 | 3.8 | 1.9 | 1.1 | 173.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +86.15% | −7.55% | −19.94% | −14.61% | −16.75% | +8.26% |
| Today | +6.50% | +3.42% | +1.49% | +1.33% | +2.81% | +3.36% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 87S.F news ›Roivant Sciences Ltd. $ROIV Position Trimmed by Inspire Investing LLC
Posted by Defense World Staff on Oct 26th, 2026 ROIV opened at $36.49 on Monday. The firm has a market cap of $26.36 billion, a price-to-earnings ratio of -68.85 and a beta of 1.10. Roivant Sciences Ltd. has a 12 month low of $17.89 and a…
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis - Slideshow
2026-10-24. The following slide deck was published by Roivant Sciences Ltd. The following slide deck was published by Roivant Sciences Ltd. in conjunction with this event.
Analyzing Verastem (NASDAQ:VSTM) and Roivant Sciences (NASDAQ:ROIV)
Posted by Defense World Staff on Oct 25th, 2026 Verastem (NASDAQ:VSTM – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
More from 1 other outlet
Roivant Sciences climbs on positive uveitis trial data
Roivant Sciences stock rose 6.8% in morning trading on Wednesday after the company and its subsidiary Priovant Therapeutics reported that brepocitinib met all primary and key secondary endpoints in two Phase 3 trials for non-infectious…
Roivant Sciences (ROIV) Jumps 6.2% to $37.10
AlphaStreet AlphaStreet Newsdesk powered by AlphaStreet Intelligence Roivant Sciences soared Wednesday, climbing 6.2% to $37.10 as investors cheered positive clinical trial results for a uveitis treatment. The biotechnology company’s…
Roivant Sciences: Venker proposes $7.02M share sale
Netflix Reports Q3 2026 Earnings: Revenue Rises 12% to $12.87 Billion, Operating Margin 34.6% Supermicro Provides First Quarter of Fiscal Year 2027 Preliminary Business Update INOVIO Announces Favorable Judgment in Litigation with VGXI,…
Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.
Posted by Defense World Staff on Oct 16th, 2026 Shares of NASDAQ ROIV opened at $34.04 on Friday. The firm has a market cap of $24.59 billion, a PE ratio of -64.23 and a beta of 1.10. Roivant Sciences Ltd. has a 1-year low of $16.88 and a…
Roivant Sciences added to Citi's 90-day catalyst watch
Seeking Alpha - Citi has added Roivant Sciences (ROIV) to its 90-day positive catalyst watch due to a release of topline data from the phase 3 CLARITY trial for brepocitinib in non-infectious uveitis coming later this quarter.
Reviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)
Posted by Tristan Rich on Oct 11th, 2026 Janux Therapeutics (NASDAQ:JANX – Get Free Report) and Roivant Sciences (NASDAQ:ROIV – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- defenseworld.net3
- themarketsdaily.com3
- seekingalpha.com2
- cnbc.com1
- news.alphastreet.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 13 articles, not a forecast.